HWG Holdings LP acquired a new stake in shares of DexCom, Inc. (NASDAQ: DXCM) in the undefined quart

Barclays analyst Christopher Pasquale initiates coverage on DexCom (NASDAQ:DXCM) with a Overweigh

[url="]DEXCOM[/url], INC. (NASDAQ: DXCM), the global leader in glucose biosensing, announced today t

SAN DIEGO--(BUSINESS WIRE)--DEXCOM, INC. (NASDAQ: DXCM), the global leader in glucose biosensing, an

The Nasdaq 100 trades at records Monday, yet 55 of its 101 stocks sit below their 50-day average. QQ

RBC Capital analyst Kendall Au maintains DexCom (NASDAQ:DXCM) with a Outperform and raises the pr

Market Overview Stocks began their breakout to new all-time highs again, but it remains a highly

New global State of Type 2 Report uncovers three interconnected challenges in Type 2 diabetes care:

Truist Securities analyst Richard Newitter maintains DexCom (NASDAQ:DXCM) with a Buy and raises t

The FDA authorized Abbott's Libre Duo 10 Day, the first wearable tracking both glucose and keton

Argus Research analyst Steve Silver maintains DexCom (NASDAQ:DXCM) with a Buy and raises the pric

Canaccord Genuity analyst William Plovanic maintains DexCom (NASDAQ:DXCM) with a Buy and raises t

Citigroup analyst Joanne Wuensch maintains DexCom (NASDAQ:DXCM) with a Buy and raises the price t

RBC Capital analyst Kendall Au maintains DexCom (NASDAQ:DXCM) with a Outperform and raises the pr

Mizuho analyst Anthony Petrone maintains DexCom (NASDAQ:DXCM) with a Outperform and raises the pr

Amazon surges 15% on an AWS blowout while Apple sheds nearly $475 billion in value. Yields sit at cy

JP Morgan analyst Robbie Marcus maintains DexCom (NASDAQ:DXCM) with a Neutral and raises the pric

Piper Sandler analyst Matt O'Brien reiterates DexCom (NASDAQ:DXCM) with a Overweight and rais

Wells Fargo analyst Larry Biegelsen maintains DexCom (NASDAQ:DXCM) with a Overweight and raises t

U.S. stocks mixed, Nasdaq up 50 pts. AXT Inc (NASDAQ: AXTI) rose 25.3% on strong Q2 results. Other g

Stifel analyst Jonathan Block maintains DexCom (NASDAQ:DXCM) with a Buy and raises the price targ

Benchmark analyst Bruce D. Jackson maintains DexCom (NASDAQ:DXCM) with a Buy and raises the price

Truist Securities analyst Richard Newitter maintains DexCom (NASDAQ:DXCM) with a Buy and raises t

BTIG analyst Marie Thibault maintains DexCom (NASDAQ:DXCM) with a Buy and raises the price target

DexCom (NASDAQ:DXCM) raises FY2026 sales outlook from $5.160 billion-$5.250 billion to $5.180 billio

DexCom (NASDAQ:DXCM) reported quarterly earnings of $0.70 per share which beat the analyst consensus

The FDA launched the TEMPO pilot to evaluate a new regulatory approach for certain digital health te

Truist Securities analyst Richard Newitter maintains DexCom (NASDAQ:DXCM) with a Buy and raises t

Mizuho analyst Anthony Petrone maintains DexCom (NASDAQ:DXCM) with a Outperform and raises the pr

Dexcom G7 15 Day is the longest‑lasting and most accurate1-4 CGM system authorized by Health Canada,

Wall Street analysts changed outlook on top names, including MCRB, SAFX. See analyst ratings page fo

Deutsche Bank analyst Kieran Ryan initiates coverage on DexCom (NASDAQ:DXCM) with a Buy rating an

FDA Clears Dexcom's OTC Stelo CGM For Children Ages 2 And Older, Expanding Access To Real-Time G

Piper Sandler analyst Matt O'Brien maintains DexCom (NASDAQ:DXCM) with a Overweight and raise

https://www.fda.gov/news-events/press-announcements/fda-clears-first-over-counter-continuous-glucose

TD Cowen analyst Joshua Jennings maintains DexCom (NASDAQ:DXCM) with a Buy and raises the price t

Mizuho analyst Anthony Petrone maintains DexCom (NASDAQ:DXCM) with a Outperform and raises the pr

DexCom CONNECT trial found G7 reduced A1C and improved glucose control in Type 2 diabetes patients n

Dexcom sponsored CONNECT randomized controlled trial expected to help establish new standard of care

Stifel analyst Jonathan Block maintains DexCom (NASDAQ:DXCM) with a Buy and raises the price targ

CONNECT study will demonstrate Dexcom CGM benefits for adults with Type 2 diabetes not using insulin

Citigroup analyst Joanne Wuensch maintains DexCom (NASDAQ:DXCM) with a Buy and raises the price t

Through ongoing quality and accounting reviews, Dexcom discovered two lots of scrapped product were

Canaccord Genuity analyst William Plovanic maintains DexCom (NASDAQ:DXCM) with a Buy and lowers t

B of A Securities analyst Travis Steed maintains DexCom (NASDAQ:DXCM) with a Buy and lowers the p

Barclays analyst Matt Miksic maintains DexCom (NASDAQ:DXCM) with a Underweight and lowers the pri

DexCom, Inc. (Nasdaq: DXCM), a global leader in continuous glucose monitoring, today announced Dexco

DexCom Sets 2030 Margin Targets, Projects Double-Digit Revenue Growth, Authorizes $1 Billion Share B